New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and ...
IRVINE, Calif., March 29, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from a human clinical study of NIAGEN®, a cutting- …